Business Standard

Cipla Ltd News

Cipla receives additional Rs 773.44 crore tax demand from income tax office

Cipla's share price declined by 0.56 per cent, ending the day's trade at Rs 1,507.50 apiece on the BSE

Cipla receives additional Rs 773.44 crore tax demand from income tax office
Updated On : 16 Jul 2024 | 6:44 PM IST

Orchid Pharma join hands with Cipla to launch new antibiotic in India

The partnership between Orchid Pharma and Cipla combines Orchid's innovative drug development capabilities with Cipla's extensive distribution network and market presence

Orchid Pharma join hands with Cipla to launch new antibiotic in India
Updated On : 28 Jun 2024 | 5:24 PM IST

Cipla to invest additional 3 mn euro in mRNA technology company Ethris

The aim is to accelerate Cipla's entry into the mRNA space and deliver innovative mRNA-based therapies, particularly targeting respiratory treatments, to patients in emerging markets

Cipla to invest additional 3 mn euro in mRNA technology company Ethris
Updated On : 18 Jun 2024 | 6:45 PM IST

F&O Alert: These 3 Nifty stocks trade with high PCR; check key levels here

May F&O expiry strategy: In general, stocks with high Open Interest based Put Call Ratio (PCR) tend to trade with a positive bias or find strong support in case of dips.

F&O Alert: These 3 Nifty stocks trade with high PCR; check key levels here
Updated On : 27 May 2024 | 9:16 AM IST

Cipla rallies 4% on US FDA approval to market Lanreotide injection

The approval for the generic version of Lanreotide Acetate is in line with Cipla's growth strategy in the complex product segment and will strengthen Cipla's position in the US market.

Cipla rallies 4% on US FDA approval to market Lanreotide injection
Updated On : 22 May 2024 | 2:17 PM IST

Cipla receives USFDA approval to market Lanreotide injection in US

Drug major Cipla on Wednesday said it has received approval from the US health regulator to market a generic medication used to treat acromegaly and other conditions. The company has received the final approval from the US Food and Drug Administration (USFDA) to market Lanreotide injection in multiple strengths, the Mumbai-based drug maker said in a statement. The company's Lanreotide Injection is therapeutic equivalent generic version of Somatuline Depot Injection, it added. The drugmaker said its product is indicated for the treatment of patients with acromegaly and gastroenteropancreatic neuroendocrine tumours. According to IQVIA (IMS Health), Somatuline Depot had sales of around USD 898 million in the US for the 12-month period ending March 2024.

Cipla receives USFDA approval to market Lanreotide injection in US
Updated On : 22 May 2024 | 1:27 PM IST

Cipla promoters sell 2.53% stake worth Rs 2,637 cr to fund philanthropy

ICICI Prudential MF, Aditya Birla Sun Life MF among top buyers

Cipla promoters sell 2.53% stake worth Rs 2,637 cr to fund philanthropy
Updated On : 15 May 2024 | 11:01 AM IST

Pre-market: GIFT Nifty hints gap-up open; Bank Nifty expiry; FII, DII flows

All you need to know before the market opens on Wednesday, May 15: How to trade Bank Nifty ahead of the weekly expiry today; track these key levels on the Nifty. Bharti Airtel, Cipla will be in focus;

Pre-market: GIFT Nifty hints gap-up open; Bank Nifty expiry; FII, DII flows
Updated On : 15 May 2024 | 7:13 AM IST

Promoter group to sell 2.53% stake worth $316 million in Cipla: Report

The promoter group will sell its stake in Cipla at a per-share price range of 1,289.5 rupees to 1,357.35 rupees, the report said

Promoter group to sell 2.53% stake worth $316 million in Cipla: Report
Updated On : 14 May 2024 | 10:17 PM IST

Cipla: Timely new launches, India outperformance key for margin gains

Brokerages maintain add/buy rating on the stock

Cipla: Timely new launches, India outperformance key for margin gains
Updated On : 14 May 2024 | 12:59 AM IST

Cipla surges 6% in weak market on upbeat management commentary

The management has guided 24.5 per cent-25.5 per cent Ebitda margin for FY25

Cipla surges 6% in weak market on upbeat management commentary
Updated On : 13 May 2024 | 10:48 AM IST

Cipla Q4 results: Net profit soars 79% on strong India and US business

Eyes further market expansion and partnerships in FY25

Cipla Q4 results: Net profit soars 79% on strong India and US business
Updated On : 10 May 2024 | 7:12 PM IST

Cipla Q4 results: Profit rises 78.5% to Rs 939 crore, revenue up 7%

Cipla Q4FY24 results: The company board has recommended a final dividend of Rs 13 per equity share, to be paid within 30 days from the date of the annual general meeting (AGM)

Cipla Q4 results: Profit rises 78.5% to Rs 939 crore, revenue up 7%
Updated On : 10 May 2024 | 3:34 PM IST

Cipla Q4 Results Preview: Profits may jump up to 75% on higher volumes

Cipla may show a 3-10 per cent jump in its topline year-on-year (Y-o-Y), registering revenues in the range of Rs 5,939 crore and Rs 6,292 crore

Cipla Q4 Results Preview: Profits may jump up to 75% on higher volumes
Updated On : 09 May 2024 | 12:40 PM IST

USFDA issues Form 483 with 1 inspectional observation to Cipla's Maha unit

Pharma major Cipla Ltd on Wednesday said it has received one inspectional observation in Form 483 from the US health regulator for its manufacturing facility at Kurkumbh in Maharashtra. As per the US Food and Drug Administration (USFDA), Form 483 is issued to a firm's management at the conclusion of an inspection when the investigator has observed any conditions that may constitute violations of the Food Drug and Cosmetic (FD&C) Act and related Acts. A routine current Good Manufacturing Practices (cGMP) inspection was conducted by the USFDA at the company's manufacturing facility at Kurkumbh, Maharashtra from April 29, 2024, to May 8, 2024, Cipla said in a regulatory filing. "On conclusion of the inspection, the company has received one inspectional observation in Form 483," it added. The company will work closely with the USFDA and is committed to addressing this observation comprehensively within the stipulated time, Cipla said.

USFDA issues Form 483 with 1 inspectional observation to Cipla's Maha unit
Updated On : 08 May 2024 | 4:23 PM IST

Anand Rathi recommends buy on Dr.Reddys, Cipla and Piramal Enterprises

Stock picks by Anand Rathi: DR Reddy shows a strong uptrend with higher highs and higher lows on a weekly scale

Anand Rathi recommends buy on Dr.Reddys, Cipla and Piramal Enterprises
Updated On : 06 May 2024 | 7:43 AM IST

Cipla gets Rs 1.83 cr penalty for claiming inadmissible transitional credit

Pharma major Cipla Ltd on Friday said it has been imposed a penalty of Rs 1.83 crore by the GST authority for claiming inadmissible transitional credit on education cess. The company has received an order from the Principal Commissioner of CGST & Central Excise, Mumbai, Maharashtra imposing a penalty of Rs 1,83,17,388 under applicable provisions of the Central Goods and Services Tax Act, 2017 and Maharashtra Goods and Services Tax Act, 2017, Cipla said in a regulatory filing. "The order has been passed by the GST Authority on the contention that the company has claimed inadmissible transitional credit on education cess during the transition from excise regime to GST regime in FY 2017-18 and has ordered recovery of the same with penalty," it added. Cipla further said that based on an assessment of facts and prevailing law, it will file necessary appeals with the appellate authority in this regard. There is no material impact on the company's financials or operations due to the said

Cipla gets Rs 1.83 cr penalty for claiming inadmissible transitional credit
Updated On : 19 Apr 2024 | 5:03 PM IST

Cipla to acquire Ivia Beaute's cosmetics, personal care biz for Rs 130 cr

Pharma major Cipla Ltd will acquire the cosmetics and personal care distribution and marketing business of Ivia Beaute Pvt Ltd, including the latter's brands Astaberry, Ikin and Bhimsaini, on a worldwide basis for Rs 130 crore, according to a regulatory filing by the company. Cipla Health Ltd (CHL), a wholly owned subsidiary and consumer healthcare arm, has signed a Business Transfer Agreement (BTA) for purchase of the distribution and marketing business undertaking of the cosmetics and personal care business of Ivia Beaute Pvt Ltd, Cipla said. This strategic move is aligned with Cipla's focus on enhancing its consumer healthcare and wellness portfolio, it added. The acquisition will include Ivia Beaute's brands namely Astaberry, Ikin and Bhimsaini on a worldwide basis, the company said. On the cost of acquisition, Cipla said it will be "Rs 130 crore on the closing date and Rs 110 crore contingent upon achievement of certain financial parameters (milestones) for next 3 years as ...

Cipla to acquire Ivia Beaute's cosmetics, personal care biz for Rs 130 cr
Updated On : 16 Apr 2024 | 11:01 AM IST

Analysts favour defensive bets as hedge against equity market downturn

From defensives, Nifty Pharma index has led gains so far in calendar year 2024 with a surge of 11 per cent, followed by Nifty IT, which is up 4 per cent while Nifty FMCG has shed 6 per cent

Analysts favour defensive bets as hedge against equity market downturn
Updated On : 15 Mar 2024 | 10:20 AM IST

Cipla receives approval from drug regulator CDSCO for UTI drug

Plazomicin is a new intravenous (IV) aminoglycoside that has demonstrated efficacy and safety in clinical trials compared to meropenem (antibacterial agent)

Cipla receives approval from drug regulator CDSCO for UTI drug
Updated On : 26 Feb 2024 | 7:28 PM IST